The open-label study of the impact of dapagliflozin to the visceral fat for diabetes patients

The open-label study of the impact of dapagliflozin to the visceral fat for diabetes patients - The open-label study of the impact of dapagliflozin to the visceral fat for diabetes patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017974

Enrollment

100

Registered

2015-07-01

Start date

2015-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes patients

Interventions

Dapagliflozin 5mg current treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: HbA1c(NGSP value) >=7.0% metabolic syndrome

Exclusion criteria

Exclusion criteria: Dapagliflozin in use History of hypersensitivity to dapagliflozin containing components Severe ketosis diabetic coma or precoma Severe infection before and after surgery severe trauma

Design outcomes

Primary

Measure	Time frame
visceral fat	—

Secondary

Measure	Time frame
clinical indicators abdominal circumference Hypoglycemia Body weight	—

Countries

Japan

Contacts

Public ContactMasaharu Hirano

Tokyo Medical University Cardiovascular medicine

m-hirano@tokyo-med.ac.jp03-3351-6141

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026